Scarica l'app Stockscreener
2.10
0.94%
-0.02
Dopo l'orario di chiusura:
2.10
Precedente Chiudi:
$2.12
Aprire:
$2.14
Volume 24 ore:
2.41M
Relative Volume:
0.93
Capitalizzazione di mercato:
$346.32M
Reddito:
$101.21M
Utile/perdita netta:
$-569.00K
Rapporto P/E:
-105.00
EPS:
-0.02
Flusso di cassa netto:
$-56.88M
1 W Prestazione:
+2.44%
1M Prestazione:
-12.13%
6M Prestazione:
+221.69%
1 anno Prestazione:
+68.00%
Intervallo 1D:
$2.02
$2.15
Intervallo di 1 settimana:
$1.99
$2.17
Portata 52W:
$0.40
$3.095
Cytomx Therapeutics Inc Stock (CTMX) Company Profile
Nome
Cytomx Therapeutics Inc
Settore
Industria
Telefono
650.515.3185
Indirizzo
151 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA
Confronta CTMX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CTMX
Cytomx Therapeutics Inc
|
2.10 | 343.02M | 101.21M | -569.00K | -56.88M | -0.02 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.93 | 102.81B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
453.54 | 58.59B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
567.22 | 61.25B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
733.66 | 43.23B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
318.73 | 36.53B | 3.81B | -644.79M | -669.77M | -6.24 |
Cytomx Therapeutics Inc Stock (CTMX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-31 | Iniziato | Oppenheimer | Outperform |
| 2025-05-15 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2025-04-14 | Ripresa | Piper Sandler | Overweight |
| 2024-05-28 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2024-05-09 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2024-05-06 | Aggiornamento | Jefferies | Hold → Buy |
| 2024-04-22 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2022-11-14 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2022-07-07 | Downgrade | Jefferies | Buy → Hold |
| 2022-07-07 | Downgrade | Mizuho | Buy → Neutral |
| 2022-07-07 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2022-07-07 | Downgrade | Wedbush | Outperform → Neutral |
| 2022-06-24 | Iniziato | BMO Capital Markets | Outperform |
| 2022-01-18 | Aggiornamento | Barclays | Underweight → Overweight |
| 2021-11-15 | Iniziato | BTIG Research | Buy |
| 2021-05-28 | Downgrade | Barclays | Equal Weight → Underweight |
| 2021-03-29 | Iniziato | JP Morgan | Overweight |
| 2021-03-23 | Aggiornamento | Jefferies | Hold → Buy |
| 2020-09-22 | Downgrade | Guggenheim | Buy → Neutral |
| 2020-06-01 | Downgrade | Jefferies | Buy → Hold |
| 2020-05-14 | Reiterato | H.C. Wainwright | Buy |
| 2020-03-24 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2020-03-04 | Iniziato | Barclays | Equal Weight |
| 2019-11-20 | Iniziato | Guggenheim | Buy |
| 2019-11-11 | Downgrade | Wedbush | Outperform → Neutral |
| 2019-06-13 | Iniziato | Mizuho | Buy |
| 2019-05-14 | Iniziato | Cantor Fitzgerald | Overweight |
| 2019-03-11 | Iniziato | Barclays | Overweight |
| 2018-11-26 | Iniziato | Piper Jaffray | Overweight |
| 2018-10-15 | Iniziato | Goldman | Neutral |
| 2018-09-13 | Iniziato | H.C. Wainwright | Buy |
| 2018-06-01 | Iniziato | SunTrust | Buy |
| 2018-01-05 | Iniziato | Citigroup | Buy |
| 2017-09-08 | Iniziato | Wedbush | Outperform |
| 2017-03-27 | Iniziato | H.C. Wainwright | Buy |
| 2017-03-02 | Iniziato | Instinet | Buy |
| 2017-01-03 | Downgrade | Oppenheimer | Outperform → Perform |
| 2015-11-02 | Iniziato | Oppenheimer | Outperform |
Mostra tutto
Cytomx Therapeutics Inc Borsa (CTMX) Ultime notizie
Real time social sentiment graph for CytomX Therapeutics Inc.July 2025 Trends & Stock Portfolio Risk Management - Newser
CytomX Therapeutics, Inc. (NASDAQ:CTMX) Q2 2025 Earnings Call Transcript - MSN
Published on: 2025-09-03 09:30:47 - Newser
How to recover losses in CytomX Therapeutics Inc. stockEntry Point & Free Community Consensus Stock Picks - Newser
What earnings revisions data tells us about CytomX Therapeutics Inc.Weekly Stock Recap & Long-Term Growth Plans - Newser
CytomX Therapeutics Inc.’s volatility index tracking explainedJuly 2025 Chart Watch & Free Weekly Chart Analysis and Trade Guides - Newser
Published on: 2025-09-03 13:30:24 - beatles.ru
What earnings revisions data tells us about CytomX Therapeutics IncJuly 2025 Levels & Weekly Momentum Stock Picks - Newser
Will CytomX Therapeutics Inc. benefit from macro trends2025 Key Lessons & AI Based Buy/Sell Signal Reports - Newser
Can you recover from losses in CytomX Therapeutics Inc.Fed Meeting & Fast Gain Stock Trading Tips - Newser
CytomX Therapeutics Inc. stock trendline breakdownJuly 2025 Action & Momentum Based Trading Ideas - Newser
How to forecast CytomX Therapeutics Inc. trends using time seriesTrade Performance Summary & Free Low Drawdown Momentum Trade Ideas - Newser
Will CytomX Therapeutics Inc. stock recover after recent drop2025 Analyst Calls & Consistent Profit Trading Strategies - Newser
Sentiment analysis tools applied to CytomX Therapeutics Inc.Weekly Investment Summary & Consistent Income Trade Ideas - Newser
Is CytomX Therapeutics Inc. showing signs of accumulationWeekly Profit Recap & Verified Technical Trade Signals - Newser
Leading vs lagging indicators on CytomX Therapeutics Inc. performanceJuly 2025 Trends & Stepwise Trade Signal Guides - Newser
Will Windtree Therapeutics Inc. outperform during market ralliesJuly 2025 Short Interest & Fast Moving Trade Plans - خودرو بانک
Can CytomX Therapeutics Inc. maintain sales growthMarket Volume Report & Smart Investment Allocation Tips - khodrobank.com
Market Outlook: Will CytomX Therapeutics Inc. benefit from AI trendsJuly 2025 Gainers & Free Expert Approved Momentum Trade Ideas - khodrobank.com
Historical volatility pattern of CytomX Therapeutics Inc. visualized2025 Technical Patterns & Long-Term Safe Investment Plans - Newser
Is CytomX Therapeutics Inc. trading at a discountJuly 2025 Patterns & AI Enhanced Market Trend Forecasts - khodrobank.com
Will CytomX Therapeutics Inc. bounce back from current supportPortfolio Risk Report & Safe Entry Trade Signal Reports - Newser
Statistical indicators supporting CytomX Therapeutics Inc.’s strengthWeekly Profit Report & AI Based Buy and Sell Signals - Newser
Is CytomX Therapeutics Inc. benefiting from innovation trendsJuly 2025 Reactions & Weekly Top Stock Performers List - khodrobank.com
Does CytomX Therapeutics Inc. meet Warren Buffett’s criteriaJuly 2025 Momentum & Long-Term Growth Portfolio Plans - khodrobank.com
Volume Summary: Will CytomX Therapeutics Inc. benefit from AI trendsLong Setup & AI Forecasted Entry and Exit Points - khodrobank.com
Tools to assess CytomX Therapeutics Inc.’s risk profileInflation Watch & Technical Pattern Based Buy Signals - Newser
Does CytomX Therapeutics Inc. fit your quant trading modelMarket Volume Report & Free Low Drawdown Momentum Trade Ideas - Newser
Can CytomX Therapeutics Inc. Rally Enough to Break Even2025 Valuation Update & Daily Entry Point Trade Alerts - beatles.ru
Can CytomX Therapeutics Inc. hit a new high this monthJuly 2025 Trends & Stepwise Trade Signal Implementation - Newser
Is CytomX Therapeutics Inc. stock bottoming outDip Buying & Risk Controlled Stock Alerts - Newser
Smart tools for monitoring CytomX Therapeutics Inc.’s price actionTrade Performance Summary & Verified High Yield Trade Plans - Newser
CytomX Therapeutics Inc. Approaches Psychological Resistance Level getLinesFromResByArray error: size == 0 - kangso.co.kr
Is CytomX Therapeutics Inc. forming higher highs and higher lows2025 Key Lessons & Risk Controlled Swing Alerts - kpenews.com
Cytomx Therapeutics Inc Azioni (CTMX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Cytomx Therapeutics Inc Azioni (CTMX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Ogden Christopher | Chief Financial Officer |
Jun 16 '25 |
Sale |
2.69 |
10,614 |
28,540 |
226,271 |
| Ogden Christopher | Chief Financial Officer |
Jun 13 '25 |
Sale |
2.95 |
1,641 |
4,841 |
199,385 |
| BELVIN MARCIA | SVP, Chief Scientific Officer |
Jun 13 '25 |
Option Exercise |
0.00 |
37,500 |
0 |
286,136 |
| BELVIN MARCIA | SVP, Chief Scientific Officer |
Jun 16 '25 |
Sale |
2.69 |
13,884 |
37,334 |
272,252 |
| McCarthy Sean A. | CEO |
Jun 13 '25 |
Option Exercise |
0.00 |
150,000 |
0 |
1,145,195 |
| McCarthy Sean A. | CEO |
Jun 16 '25 |
Sale |
2.69 |
55,511 |
149,264 |
1,089,684 |
| McCarthy Sean A. | CEO |
Mar 18 '25 |
Sale |
0.60 |
37,656 |
22,556 |
995,195 |
| Ogden Christopher | Chief Financial Officer |
Mar 18 '25 |
Sale |
0.60 |
8,551 |
5,122 |
201,026 |
| Chu Yu-Waye | Chief Medical Officer |
Mar 18 '25 |
Sale |
0.60 |
4,025 |
2,411 |
135,725 |
| ROWLAND LLOYD A | General Counsel |
Mar 18 '25 |
Sale |
0.60 |
10,203 |
6,112 |
120,594 |
1.75%
1.11%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):